

2018 Blue Cross NC Provider Quality Pocket Guide



**BlueCross BlueShield
of North Carolina**

TABLE OF CONTENTS

MEASURE ABBREVIATION	MEASURE DESCRIPTION	PAGE
AAB	Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis	3
ABA	Adult BMI Assessment	4
ADD	Follow Up Care for Children Prescribed ADHD Medication	5
AMM	Antidepressant Medication Management	5
AMR	Asthma Medication Ratio	6
ART	Disease Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis	6
AWC	Adolescent Well-Care Visits	7
BCS	Breast Cancer Screening	7
CBP	Controlling High Blood Pressure	8
CCS	Cervical Cancer Screening	8
CDC	Comprehensive Diabetes Care - HbA1c	9
	Comprehensive Diabetes Care - Medical Attention for Nephropathy	10
	Comprehensive Diabetes Care - BP control	11
	Comprehensive Diabetes Care - Eye Exam	11
CHL	Chlamydia Screening in Women (16-24 years of age)	12
CWP	Appropriate Testing for Children with Pharyngitis	13
CIS	Childhood Immunization Status	13
COL	Colorectal Cancer Screening	14
FUH	Follow up after Hospitalization for Mental Illness	15
IMA	Immunizations for Adolescents	15
IET	Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment	16
LBP	Use of Imaging Studies for Low Back Pain	17
MPM	Annual Monitoring for Patients on Persistent Medications	17
MMA	Medication Management for People with Asthma	18
NCS	Non-recommended Cervical Cancer Screening in Adolescent Females	19

TABLE OF CONTENTS (CONTINUED)

MEASURE ABBREVIATION	MEASURE DESCRIPTION	PAGE
OMW	Osteoporosis Management in Women Who Had a Fracture	19
PBH	Persistence of Beta Blocker Treatment after a Heart Attack	20
PCE	Pharmacotherapy Management of COPD Exacerbation (Systemic Corticosteroid)	21
	Pharmacotherapy Management of COPD Exacerbation (Bronchodilator)	21
PPC	Timeliness of Prenatal Care	21
	Postpartum Care	21
SPC	Statin Therapy for Patients With Cardiovascular Disease	22
SPD	Statin Therapy for Patients With Diabetes	23
SPR	Use of Spirometry Testing for Assessment and Diagnosis of COPD	23
URI	Appropriate Treatment for Children with Upper Respiratory Infections	24
W15	Well-Child Visits in the first 15 months of Life	24
W34	Well Child Visits in the 3rd, 4th, 5th, and 6th Years of Life	25
WCC	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Total - BMI Percentile	25
	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Total - Nutrition	26
	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Total - Physical Activity	27
Medicare Part D	Medicare Part D Measures	28-30
Appendix 1	BMI Code Chart	31
Appendix 2	BMI Chart	32
Appendix 3	Measures Used in Overall Medicare Star Ratings	33
Appendix 4	MIPS-HEDIS measure crosswalk	34-36

This reference guide is not intended to be a complete guide for all HEDIS measures and requirements. For additional details and specifications for HEDIS measures please go to <http://www.ncqa.org/hedis-quality-measurement/hedis-measures/hedis-2018>.

DEFINITIONS

Administrative Measure - Measure compliance is assessed by claims only

Hybrid Measure - Medical Records may be required for assessment of measure compliance

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL																								
<p>AAB – Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis MIPS Measure #116 Administrative measure</p> <p>The percentage of adults 18-64 years of age with a diagnosis of acute bronchitis who were NOT dispensed an antibiotic prescription.</p> <p>The Intake period is 1/1 to 12/24 each year.</p>	<p>Members treated for acute bronchitis (J20.3-J20.9) should NOT be prescribed antibiotics unless there are co-morbid conditions (see table) or competing diagnoses that require antibiotic therapy.</p> <p><i>NOTE: Asthma (J45), Tobacco use (F17 or Z72.0), wheezing (R06.2), fever (R50.9), and Diabetes (E08 – E13) are <u>not</u> co-morbid or competing diagnosis exclusions.</i></p>	<p>Claims:</p> <ul style="list-style-type: none"> Submit a claim with all appropriate diagnosis codes including any competing conditions (i.e. cellulitis) and any co-morbid condition diagnoses. <table border="1" data-bbox="679 477 1312 853"> <thead> <tr> <th>EXCLUSIONS/CO-MORBID CONDITIONS</th> <th>ICD -10 CM</th> </tr> </thead> <tbody> <tr> <td>HIV</td> <td>B20, Z21, B97.35</td> </tr> <tr> <td>Malignant Neoplasms</td> <td>C00.0 – C96.9, Z85.0 – Z85.9</td> </tr> <tr> <td>Emphysema</td> <td>J43.0 – J43.9</td> </tr> <tr> <td>COPD</td> <td>J44.0 – J44.9</td> </tr> <tr> <td>Cystic Fibrosis</td> <td>E84.0 – E84.9</td> </tr> <tr> <td>Chronic Bronchitis</td> <td>J41.0 – J42</td> </tr> <tr> <td>Disorders of the Immune System</td> <td>D80.0 – D84.9, D89.3 – 89.9</td> </tr> <tr> <td>Other respiratory diagnoses</td> <td>J22, J47.0, J47.1, J47.9, J60 – J96.92, J99, M30.1, M32.13, M33.01, M33.11, M33.21, M33.91, M34.81, M35.02</td> </tr> <tr> <td>TB</td> <td>A15 – A19.9, 098.011 – 098.03</td> </tr> <tr> <td>Aspergillosis</td> <td>B44.81</td> </tr> <tr> <td>Sickle Cell Disease with Acute Chest</td> <td>D57.01, D57.211, D57.411, D57.811</td> </tr> </tbody> </table> <p>Medical Record documentation not applicable. A comprehensive list of medications and NDC codes can be found at www.ncqa.org</p>	EXCLUSIONS/CO-MORBID CONDITIONS	ICD -10 CM	HIV	B20, Z21, B97.35	Malignant Neoplasms	C00.0 – C96.9, Z85.0 – Z85.9	Emphysema	J43.0 – J43.9	COPD	J44.0 – J44.9	Cystic Fibrosis	E84.0 – E84.9	Chronic Bronchitis	J41.0 – J42	Disorders of the Immune System	D80.0 – D84.9, D89.3 – 89.9	Other respiratory diagnoses	J22, J47.0, J47.1, J47.9, J60 – J96.92, J99, M30.1, M32.13, M33.01, M33.11, M33.21, M33.91, M34.81, M35.02	TB	A15 – A19.9, 098.011 – 098.03	Aspergillosis	B44.81	Sickle Cell Disease with Acute Chest	D57.01, D57.211, D57.411, D57.811
EXCLUSIONS/CO-MORBID CONDITIONS	ICD -10 CM																									
HIV	B20, Z21, B97.35																									
Malignant Neoplasms	C00.0 – C96.9, Z85.0 – Z85.9																									
Emphysema	J43.0 – J43.9																									
COPD	J44.0 – J44.9																									
Cystic Fibrosis	E84.0 – E84.9																									
Chronic Bronchitis	J41.0 – J42																									
Disorders of the Immune System	D80.0 – D84.9, D89.3 – 89.9																									
Other respiratory diagnoses	J22, J47.0, J47.1, J47.9, J60 – J96.92, J99, M30.1, M32.13, M33.01, M33.11, M33.21, M33.91, M34.81, M35.02																									
TB	A15 – A19.9, 098.011 – 098.03																									
Aspergillosis	B44.81																									
Sickle Cell Disease with Acute Chest	D57.01, D57.211, D57.411, D57.811																									

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>ABA – Adult BMI Assessment Hybrid measure</p> <p>The percentage of members 18-74 years of age whose body mass index (BMI) or BMI percentile, was documented during the measurement year or the year prior to the measurement year.</p> <p>The measurement period is 1/1 to 12/31 each year.</p> <p>Similar to MIPS Measure #128; see Appendix 4 for details.</p>	<p>For patients 20-74 years of age document weight and BMI value, at least every 2 years.</p> <p>For patients 18-19 years of age, document height, weight and BMI percentile at least every 2 years.</p>	<p>Claims:</p> <ul style="list-style-type: none"> ▪ Submit a claim for patients 20-74 with the appropriate ICD10 CM code for BMI Z68.1 – Z68.45* ▪ Submit a claim for patients 18 to 20 with the appropriate ICD10 CM code for BMI percentile Z68.51 to Z68.54* <p>* These codes are not currently eligible for reimbursement; correct coding guidelines still apply.</p> <p>Medical Record documentation of:</p> <ul style="list-style-type: none"> ▪ Weight and BMI value (for ages 20-74), or Weight, Height, and BMI percentile (for ages 18-19), within the measurement year or the prior year. <p><i>See Appendix 1 and 2 for ICD10 codes for BMI and BMI percentiles.</i></p>

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>ADD – Follow Up Care for Children Prescribed ADHD Medication. MIPS Measure #366 Administrative measure</p> <p>The percentage of children (6-12 years of age as of the Prescription Start Date) newly prescribed, or <i>restarting a medication commonly used for ADHD following a lapse of 120 days</i>, who had at least three follow-up care visits within a 10-month period, <i>one of which was with a prescribing provider within 30 days of when the medication was dispensed.</i></p> <p>The Intake period is 3/1 of the prior year to 2/29 of the current year.</p>	<p>Initiation Phase: The member must have an appointment with a provider with prescribing authority for a follow up visit within 30 days of starting or restarting a medication commonly used to treat ADHD.</p> <p>Continuation and Maintenance Phase: Then the member must have at least 2 additional follow up visits after the Initiation visit within the next 9 months.</p>	<p>Claims:</p> <ul style="list-style-type: none"> Submit a claim for a follow up visit with a prescribing provider and the appropriate CPT and ICD10 ADHD codes within 30 days of starting the medication and then at least 2 additional visits with a provider in the 9 months following the 30 day visit. Please use the Patient Care Summary to verify the date of medication fills and refills. <p>Medical record documentation not applicable.</p> <p><i>A comprehensive list of medications and NDC codes can be found at www.ncqa.org.</i></p>

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>AMM – Antidepressant Medication Management MIPS Measure #9 Administrative measure</p> <p>The percentage of members 18 years of age and older with a diagnosis of major depression who were treated with antidepressant medication and who remained on the medication treatment for:</p> <ul style="list-style-type: none"> 84 days (12 weeks) - Acute Phase. 180 days (6 months) - Continuation Phase. <p>The Intake period is 5/1 of the prior year to 4/30 of the current year.</p>	<p>Members with a diagnosis of Major Depressive disorder will remain on medication therapy for at least 180 days (6 months) - Continuation Phase</p>	<p>Claims:</p> <ul style="list-style-type: none"> Submit a claim for the appropriate member diagnosis. Receipt of pharmacy claims for 6 months of medication fill. <p>Medical record documentation not applicable.</p> <p><i>Members placed on antidepressant therapy for other disorders such as episodic mood disorders, anxiety disorders, acute reaction to stress, or adjustment disorder are not included in this measure.</i></p> <p><i>A comprehensive list of medications and NDC codes can be found at www.ncqa.org.</i></p>

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL												
<p>AMR – Asthma Medication Ratio Administrative measure</p> <p>The percentage of members 5-64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year.</p> <p>The measurement period is 1/1 to 12/31 each year.</p>	<p>Patients with persistent asthma will receive Asthma <u>controller</u> prescriptions that account for at least 50% of their total asthma medications. (Controller meds versus rescue medications.)</p>	<p>Claims:</p> <ul style="list-style-type: none"> Receipt of claims for any excursions that apply. Receipt of claims for asthma controller medications that account for at least 50% of all asthma medication prescriptions filled. <table border="1" data-bbox="686 288 1310 418"> <thead> <tr> <th colspan="2">EXCLUSIONS</th> </tr> </thead> <tbody> <tr> <td>Emphysema</td> <td>J43.0 – J43.9, J98.2, J98.3</td> </tr> <tr> <td>COPD</td> <td>J44.0 – J44.9</td> </tr> <tr> <td>Chronic conditions due to inhaled fumes/vapors</td> <td>J68.4</td> </tr> <tr> <td>Cystic Fibrosis</td> <td>E84.0 – E84.9</td> </tr> <tr> <td>Acute Respiratory Failure</td> <td>J96.00 – J96.22</td> </tr> </tbody> </table> <p>Medical record documentation not applicable. Not applicable to Medicare patients.</p> <p><i>A comprehensive list of medications and NDC codes can be found at www.ncqa.org</i></p>	EXCLUSIONS		Emphysema	J43.0 – J43.9, J98.2, J98.3	COPD	J44.0 – J44.9	Chronic conditions due to inhaled fumes/vapors	J68.4	Cystic Fibrosis	E84.0 – E84.9	Acute Respiratory Failure	J96.00 – J96.22
EXCLUSIONS														
Emphysema	J43.0 – J43.9, J98.2, J98.3													
COPD	J44.0 – J44.9													
Chronic conditions due to inhaled fumes/vapors	J68.4													
Cystic Fibrosis	E84.0 – E84.9													
Acute Respiratory Failure	J96.00 – J96.22													

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>ART – Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis Administrative Measure</p> <p>The percentage of members who were diagnosed with rheumatoid arthritis & who were dispensed at least 1 prescription for a DMARD medication. The measurement period is 1/1 to 12/31 of the current year. See Appendix 4 for MIPS Measure #180 information</p>	<p>Member will receive at least one ambulatory prescription for Disease-Modifying Anti-Rheumatic Drug (DMARD) Therapy.</p> <p>All patients with RA diagnosis not currently treated with a DMARD should be referred for a rheumatology consult to confirm diagnosis & assess for DMARD therapy.</p>	<p>Claims:</p> <ul style="list-style-type: none"> Receipt of claims for any exclusions that apply Submit a claim for exclusions that apply. <ul style="list-style-type: none"> > HIV anytime during the member’s history to 12/31 of the measurement year > Pregnancy anytime during the measurement year <p>Medical record documentation not applicable.</p> <p><i>A comprehensive list of medications and NDC codes can be found at www.ncqa.org</i></p>

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>AWC - Adolescent Well-Care Visits</p> <p>The percentage of enrolled members 12-21 years of age who had at least one comprehensive well-care visit with a PCP or an OB/GYN practitioner during the measurement year.</p>	<p>Every Adolescent between ages 12 and 21 will have at least one comprehensive well-care visit with a PCP or an OB/GYN practitioner every year.</p>	<p>Claims:</p> <ul style="list-style-type: none"> Submit a claim for all member visits with proper coding for the visit service. <p>Medical record documentation not applicable.</p>

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>BCS – Breast Cancer Screening</p> <p>MIPS Measure #112 Administrative Measure</p> <p>The percentage of women 50-74* years of age who had a mammogram to screen for breast cancer.</p> <p>The measurement period is 1/1 to 12/31 of the current year.</p> <p>There is a 27 month look back period from 10/1 two years prior to 12/31 of the current year.</p>	<p>Members between the age of 52 and 74 years will have one or more mammograms at least every 2 years.</p> <p>Educate your patients on the importance breast cancer screening.</p>	<p>Claims:</p> <ul style="list-style-type: none"> Receipt of a claim for mammogram from the radiology facility where the mammogram was performed anytime between October 1st two years prior to the measurement year and 12/31 of the measurement year. Submit a claim for exclusions: <ul style="list-style-type: none"> > ICD10 Z90.13 for history of bilateral mastectomy or > Z90.11 Absence of right breast and Z90.12 Absence of left breast. <p><i>This measure assesses the use of imaging to detect early breast cancer in women. Because the measure denominator does not remove women at higher risk of breast cancer, all types and methods of mammograms (screening, diagnostic, film, digital or digital breast tomosynthesis) qualify for numerator compliance.</i></p> <p>Do not count MRIs, ultrasounds or biopsies towards the numerator, although they may be indicated for evaluating women at higher risk for breast cancer or for diagnostic purposes. These procedures are performed as an adjunct to mammography and do not alone count toward the numerator.</p> <p>*Medicare excludes members 65 years of age and older living in long-term institutional settings from this measure.</p>

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>CBP – Controlling High Blood Pressure MIPS Measure #236 Hybrid measure</p> <p>The percentage of members 18-85* years of age who had a dx of hypertension (HTN) and whose BP was controlled during the measurement year.</p> <ul style="list-style-type: none"> ▪ 18-59: BP goal <140/90 ▪ 60-85 with dx of diabetes: BP goal <140/90 ▪ 60-85 without dx of diabetes: BP goal <150/90 mm Hg <p>The measurement period is 1/1 to 12/31 of the current year.</p>	<p>Control of high BP is extremely important to prevent additional cardiovascular conditions.</p> <p>Educate on risk factors associated with poor control.</p> <p>Assess medication compliance.</p> <p>Inform patients of their goal BP.</p> <p>Encourage patient to obtain a BP cuff and log BP at least 3 times a week.</p>	<p>Compliance for this measure is assessed annually as part of the HEDIS hybrid medical review. Claims coding and supplemental data cannot be utilized for official HEDIS reporting gap closure.</p> <p>Medical record documentation of:</p> <ul style="list-style-type: none"> ▪ Diagnosis of HTN any time before July 1 of measurement year. ▪ The most recent BP recording in the patient record is used for the measure. <p>*Medicare excludes members 65 years of age and older living in long-term institutional settings from this measure.</p>

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL								
<p>CCS – Cervical Cancer Screening MIPS Measure #309 Hybrid measure</p> <p>The percentage of women 21-64 years of age who were screened for cervical cancer.</p> <p>The measurement period is 1/1 to 12/31 of the current year.</p>	<p>Women 21-64 will have a cervical cytology (Pap smear) every 3 years</p> <p style="text-align: center;">OR</p> <p>Women age 30-64 will have cervical cytology with HPV co-testing every 5 years.</p> <p>(Note: HPV reflex testing does not count)</p>	<p>Claims:</p> <ul style="list-style-type: none"> ▪ Submit a claim for procedures completed with appropriate codes. ▪ Submit a claim using appropriate ICD10 code for history of exclusion. <table border="1" data-bbox="691 640 1310 747"> <thead> <tr> <th colspan="2" data-bbox="691 640 1310 664">ICD-10-CM CODES FOR EXCLUSIONS</th> </tr> </thead> <tbody> <tr> <td data-bbox="691 667 1100 691">Agenesis and Aplasia of Cervix</td> <td data-bbox="1105 667 1310 691">Q51.5</td> </tr> <tr> <td data-bbox="691 694 1100 717">Acquired Absence of cervix and uterus</td> <td data-bbox="1105 694 1310 717">Z90.710</td> </tr> <tr> <td data-bbox="691 721 1100 744">Acquired Absence of cervix with remaining uterus</td> <td data-bbox="1105 721 1310 744">Z90.712</td> </tr> </tbody> </table> <p>Medical Record documentation of:</p> <ul style="list-style-type: none"> ▪ Screening and results from appropriate testing completed in the last 3-5 years ▪ Exclusions (documentation of “total”, “radical”, “complete” abdominal or vaginal hysterectomy, or any of the above listed conditions). 	ICD-10-CM CODES FOR EXCLUSIONS		Agenesis and Aplasia of Cervix	Q51.5	Acquired Absence of cervix and uterus	Z90.710	Acquired Absence of cervix with remaining uterus	Z90.712
ICD-10-CM CODES FOR EXCLUSIONS										
Agenesis and Aplasia of Cervix	Q51.5									
Acquired Absence of cervix and uterus	Z90.710									
Acquired Absence of cervix with remaining uterus	Z90.712									

CDC – Comprehensive Diabetes Care – Hybrid Measures – The percentage of members 18-75 years of age with diabetes (type 1 and type 2) who had the following during the measurement period (1/1 - 12/31 of the current year):

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>CDC HbA1c</p> <p>Three rates are reported:</p> <ol style="list-style-type: none"> HbA1c Testing HbA1c Poor Control >9% HbA1c Good Control <8% <p>MIPS Measure #1 = CDC HbA1c Poor Control >9%</p>	<ul style="list-style-type: none"> Members will have a HbA1c test performed during the measurement year HbA1c value – poor control $\geq 9\%$ (reported in PQR as inverted rate < 9%) HbA1c value Good control >8%. 	<p>Claims:</p> <ul style="list-style-type: none"> Submit a claim identifying the results of the HbA1c utilizing one of the following three CPTII codes <ul style="list-style-type: none"> > 3046F - HbA1c >9%. > 3045F - HbA1c between 7.0 - 9.0%.* > 3044F - HbA1c less than 7.0%. * CPTII code 3045F (HbA1c 7.0-9.0%) is not specific enough to denote numerator compliance. Blue Cross NC will need to use other sources (laboratory value, chart reviews) to identify if the HbA1c was <8%. <p>Medical Record documentation of:</p> <ul style="list-style-type: none"> Date and value of last HbA1c result during the measurement year

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>CDC – Medical Attention for Nephropathy MIPS measure #119</p> <p>Annual screening test or evidence of treatment for nephropathy with ACE/ARB therapy.</p>	<p>Members will have an annual urine screen for albumin/protein done during the measurement year.</p> <p style="text-align: center;">OR</p> <p>Evidence of treatment for nephropathy.</p> <p style="text-align: center;">OR</p> <p>ACE/ARB therapy.</p>	<p>Claims:</p> <ul style="list-style-type: none"> ▪ Submit a claim identifying nephropathy screen or evidence of nephropathy during the measurement year. Can accomplish by utilizing one of the following CPTII codes: <ul style="list-style-type: none"> > 3060F or 3061F - Screening tests for nephropathy. > 3062F - positive macroalbuminuria. > 3066F - documentation of treatment for nephropathy. > 4010F - patient prescribed or taking ACE or ARB. <p>Medical record documentation of:</p> <ul style="list-style-type: none"> ▪ Results of nephropathy screen during the measurement year. ▪ Evidence of nephropathy during the measurement year. ▪ ACE/ARB Therapy prescribed during the measurement year.

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
CDC – BP Control <140/90	Members with diabetes will have blood pressure control of <140/90mm Hg.	<p>Claims:</p> <ul style="list-style-type: none"> ▪ Submit a claim with the 2 appropriate CPTII codes to report results of the BP. <ul style="list-style-type: none"> > 3074F Systolic BP <130mm Hg. > 3075F Systolic BP 130-139mm Hg. > 3077F Systolic BP ≥ 140mm Hg. ▪ Results of most recent blood pressure within the measurement period. <p>Medical record documentation of:</p> <ul style="list-style-type: none"> ▪ Results of most recent blood pressure within the measurement period. <p>Note: CDC BP control has different specifications than the Controlling High Blood Pressure (CBP) measure. Coding is allowed for CDC-BP measure to close care gaps, however this is not the case for CBP.</p>

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
CDC – Eye Exam MIPS Measure #117	Member will have: <ul style="list-style-type: none"> ▪ A retinal or dilated eye exam by an eye care professional (optometrist or ophthalmologist) in the measurement year. ▪ A negative retinal or dilated eye exam (negative for retinopathy) by an eye care professional in the year prior to the measurement year. ▪ Bilateral eye enucleation anytime during the member's history through December 31 of the measurement year. (NEW) 	<p>Claims:</p> <p>If you have or reviewed a report from the patient's ophthalmologist or optometrist:</p> <ul style="list-style-type: none"> ▪ Submit a claim with the appropriate CPTII code: <ul style="list-style-type: none"> > 2022F Dilated eye exam with interpretation by an ophthalmologist or optometrist documented and reviewed. > 2024F Seven (7) standard field stereoscopic photos with interpretation by an ophthalmologist or optometrist documented and reviewed. > 2026F Eye Imaging validated to match diagnosis from seven (7) standard field stereoscopic photos results documented and reviewed. > 3072F Low risk for retinopathy (no evidence of retinopathy in the prior year) <p>Medical record documentation of:</p> <ul style="list-style-type: none"> ▪ Results of most recent eye exam by an eye care professional within the measurement year or within 2 years if documented low risk of retinopathy or evidence of bilateral eye enucleation/acquired absence in both eyes anytime in member's history.

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>CHL – Chlamydia Screening in Women ages 16-24 MIPS Measure #310 Administrative measure</p> <p>The percentage of women 16-24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement year.</p> <p>The measurement year is 1/1 to 12/31 of the current year.</p>	<p>Annual screening for chlamydia is required for all sexually active females ages 16-24.</p> <p>Obtain a urine sample or obtain a direct sample (i.e., cervix, urethra, vagina) for chlamydia culture yearly.</p>	<p>Claims:</p> <ul style="list-style-type: none"> Receipt of a Microbiology claim for chlamydia screening with appropriate CPT or LOINC codes <p>Medical record documentation not applicable.</p>

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL						
<p>CWP – Appropriate Testing for Children with Pharyngitis MIPS Measure #66 Administrative measure</p> <p>The percentage of children 3-18 years of age who were diagnosed with pharyngitis dispensed an antibiotic and had a group A streptococcus (strep) test.</p> <p>The measurement period is 7/1 of the prior year to 6/30 of the current year.</p>	<p>Children 3-18 years of age diagnosed with pharyngitis/tonsillitis must receive a strep test prior to receiving a prescription for antibiotics.</p> <p><i>Other family members with strep, parental refusal or clinical exam are not exclusions to this measure.</i></p>	<p>Claims:</p> <ul style="list-style-type: none"> Submit a claim for a rapid strep test done in your office or send specimen for culture. Submit a claim for all additional competing diagnoses that would require antibiotic therapy. <p>Medical record documentation not applicable.</p> <table border="1" data-bbox="682 394 1310 472"> <thead> <tr> <th colspan="2">CWP VALUE SET</th> </tr> </thead> <tbody> <tr> <td>ICD 10 CWP value set</td> <td>J02 all codes - Pharyngitis J03 all codes - Tonsillitis</td> </tr> </tbody> </table> <p>IF YOU USE ONE OF THE CODES ABOVE, THE MEASURE REQUIRES A STREP TEST.</p> <table border="1" data-bbox="682 472 1310 550"> <tbody> <tr> <td>CPT strep test codes (LOINC codes also acceptable)</td> <td>87070, 87071, 87081, 87430, 87650, 87651, 87652, 87880</td> </tr> </tbody> </table>	CWP VALUE SET		ICD 10 CWP value set	J02 all codes - Pharyngitis J03 all codes - Tonsillitis	CPT strep test codes (LOINC codes also acceptable)	87070, 87071, 87081, 87430, 87650, 87651, 87652, 87880
CWP VALUE SET								
ICD 10 CWP value set	J02 all codes - Pharyngitis J03 all codes - Tonsillitis							
CPT strep test codes (LOINC codes also acceptable)	87070, 87071, 87081, 87430, 87650, 87651, 87652, 87880							

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>CIS – Childhood Immunization Status MIPS Measure #240 Hybrid measure</p> <p>The percentage of children 2 years of age who had all the listed immunizations.</p> <p>The measurement period is 1/1 to 12/31 of the current year.</p>	<p>By the 2nd birthday children will have the following vaccinations:</p> <ul style="list-style-type: none"> 4 DTaP 3 IPV 1 MMR 3 HiB 3 HepB 1 VZV 4 PCV 1 HepA 2 or 3 Rotavirus 2 flu vaccinations 	<p>Claims:</p> <ul style="list-style-type: none"> Report all immunizations to the North Carolina Immunization Registry. Submit a claim for all immunizations given. <ul style="list-style-type: none"> > Exclude children who had a contraindication for a specific vaccine, or anaphylactic reaction to the vaccine or its components any time on or before the member's 2nd birthday. <p>Medical record documentation:</p> <ul style="list-style-type: none"> A note indicating the name of the specific antigen and the date of the immunization or A certificate of immunization prepared by an authorized health care provider or agency including the specific dates and types of immunizations administered.

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>COL – Colorectal Cancer Screening MIPS Measure #113 Hybrid measure</p> <p>The percentage of members 50-75* years of age who had appropriate screening for colorectal cancer.</p> <p>The measurement period is 1/1 to 12/31 of the current year.</p>	<p>The member will have one of the following screening tests during the indicated period.</p> <ul style="list-style-type: none"> ▪ Fecal occult blood test (FOBT or FIT) between 1/1 and 12/31 of the measurement year.** ▪ Flexible sigmoidoscopy performed between 1/1 four (4) years prior to the measurement year and 12/31 of the measurement year. ▪ Colonoscopy performed between 1/1 nine (9) years prior to the measurement year and 12/31 of the measurement year. ▪ FIT-DNA test done between 1/1 two (2) years prior to the measurement year and 12/31 of the measurement year. <p><i>**FOBT tests performed on a sample collected from a digital rectal exam do not meet the measure requirements.</i></p>	<p>Claims:</p> <ul style="list-style-type: none"> ▪ Submit claims for 3 Fecal Occult Blood (FOBT) or 1 Fecal Immunochemical (FIT) test using code 82270, 82274, or G0328. ▪ Receipt of a claim for a sigmoidoscopy ▪ Receipt of a claim for a colonoscopy ▪ Receipt of a claim for CT colonography ▪ Receipt of a claim for 1 FIT-DNA testing ▪ Submit a claim for exclusion (Personal History of Other Malignant Neoplasm of the Large Intestines (ICD 10 = Z85.038)* or Personal History of Other Malignant Neoplasm of the rectum, rectosigmoid junction and anus (ICD10 Z85.048)*) <p>Medical record documentation of:</p> <ul style="list-style-type: none"> ▪ FOBT (3) done during the measurement year ▪ FIT (1) done during the measurement year ▪ Sigmoidoscopy done within 4 years prior to the measurement year and 12/31 of the measurement year ▪ Colonoscopy done within 9 years prior to the measurement year and 12/31 of the measurement year ▪ CT Colonography done within 4 years prior to the measurement year and 12/31 of the measurement year ▪ FIT- DNA test done within 2 years prior to the measurement year and 12/31 of the measurement year ▪ Documentation of exclusion: at any time during the member's history through 12/31 of the measurement year of colorectal cancer or a total colectomy. <p>* Medicare excludes members 65 years of age and older living in long-term institutional settings from this measure.</p>

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>FUH – Follow-Up After Hospitalization for Mental Illness MIPS Measure #391 Administrative measure</p> <p>The percentage of discharges for members 6 years & older who were hospitalized for treatment of selected mental illness diagnoses and who had an outpatient visit, an intensive outpatient encounter or partial hospitalization with a mental health practitioner.</p> <p>Two rates are reported:</p> <ol style="list-style-type: none"> 1) Follow up within 7 days after discharge (cannot count day of discharge). 2) Follow up within 30 days of discharge. The intake period is 1/1 to 12/1 each year. 	<p>The goal is:</p> <ol style="list-style-type: none"> 1) Members that had an inpatient hospitalization for a mental health diagnoses will be seen by a mental health practitioner within 7 days of discharge. 2) Members that had an inpatient hospitalization for a mental health diagnoses will be seen by a mental health practitioner within 30 days of discharge. <p><i>Follow up with a PCP does not meet the measure. The visit must be with a behavioral health practitioner.</i></p>	<p>Claims:</p> <ul style="list-style-type: none"> ▪ Receipt of a claim for an outpatient visit, intensive outpatient visit or partial hospitalization with a mental health practitioner on or within 7 days after discharge, and again within 30 days of discharge. Telehealth modifiers have been added for HEDIS 2018. <p>Medical record documentation not applicable.</p>

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>IMA – Immunizations for Adolescents Hybrid measure</p> <p>The percentage of adolescents 13 years of age who had the listed vaccinations.</p> <p>The measurement period is 1/1 to 12/31 each year.</p>	<p>By the 13th birthday, members will have received:</p> <ul style="list-style-type: none"> ▪ 1 meningococcal vaccine on or between 11th and 13th birthdays. ▪ 1 Tdap vaccine on or between 10th and 13th birthdays. ▪ 2 or 3 HPV vaccines with different dates of service on or between the member's 9th and 13th birthdays. <ul style="list-style-type: none"> – If reporting only 2 vaccines, there must be at least 146 days between the first and second dose of the HPV vaccine. 	<p>Claims:</p> <ul style="list-style-type: none"> ▪ Submit a claim for all vaccinations members receive. ▪ Report all immunizations to the North Carolina Immunization Registry. ▪ Submit a claim for exclusion if appropriate. <ul style="list-style-type: none"> > Exclude adolescents who had a contraindication for a specific vaccine. > Anaphylactic reaction to the vaccine or its components or anaphylactic reaction – serum any time on or before the member's 13th birthday. <p>Medical record documentation of:</p> <ul style="list-style-type: none"> ▪ A note indicating the name of the specific antigen & the date of the immunization or ▪ A certificate of immunization prepared by an authorized health care provider or agency, including the specific dates and types of immunizations administered.

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL								
<p>IET – Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment MIPS Measure #394 Administrative measure</p> <p>The percentage of <u>adolescent and adult</u> members, 13 years and older with a new episode of alcohol or other drug (AOD) dependence who received the following:</p> <p>Initiation - The percentage of members who initiate treatment through an outpatient visit, inpatient AOD admission, intensive outpatient encounter or partial hospitalization within 14 days of the diagnosis.</p> <p>Engagement: The percentage of members who initiated treatment and had two or more additional services with a diagnosis of AOD within 30 days of the initiation visit. The intake period is 1/1 to 11/14 each year.</p>	<p>Members who are diagnosed with alcohol or drug dependence will be referred immediately to an appropriate provider for treatment of alcohol or other drug abuse or dependence.</p> <p style="text-align: center;">OR</p> <p>Schedule a follow up visit within 14 days at your practice, to initiate treatment of AOD dependence and then 2 additional follow up visits for AOD treatment in the 30 days following the Initiation visit.</p> <p><i>If member is noncompliant with Initiation within 14 days the member is then noncompliant for both Initiation and Engagement.</i></p>	<p>Claims:</p> <ul style="list-style-type: none"> ▪ Receipt of a claim for a visit to a behavioral health provider, OR ▪ Receipt of a claim for follow up visit with the provider who diagnosed the AOD dependence within 14 days of the AOD diagnosis, utilizing an appropriate treatment code for AOD diagnosis. ▪ Receipt of a claim for 2 additional visits for AOD treatment in the 30 days following the first treatment visit. <p><i>Inform the behavioral health provider they are required to use an AOD dependence diagnosis code to meet the measure. (i.e. anxiety [F41] does not meet the measure for AOD treatment. The provider needs to use alcohol induced anxiety disorder [F10.280]).</i></p> <p>Medical record documentation not applicable.</p> <table border="1" data-bbox="682 502 1315 640"> <thead> <tr> <th data-bbox="682 502 996 557">CODES TO IDENTIFY AOD DEPENDENCE</th> <th data-bbox="996 502 1315 557">NOT INCLUDED REMISSION AND OTHER CODES</th> </tr> </thead> <tbody> <tr> <td data-bbox="682 557 996 583">F10.10 - 10.29, F11.10 - 11.29, F12.10 - 12.29</td> <td data-bbox="996 557 1315 583">F10.21, F10.9, F11.21, F11.9, F12.21, F12.9</td> </tr> <tr> <td data-bbox="682 583 996 609">F13.10 - 13.29, F14.10 - 14.29, F15.10 - 15.29</td> <td data-bbox="996 583 1315 609">F13.21, F13.9, F14.21, F14.9, F15.21, F15.9</td> </tr> <tr> <td data-bbox="682 609 996 640">F16.10 - 16.29, F18.10 - 18.29, F19.10 - 19.29</td> <td data-bbox="996 609 1315 640">F16.21, F16.9, F18.21, F18.9, F19.21, F19.9</td> </tr> </tbody> </table> <p>Primary care clinicians can provide and bill for counseling without conducting a review of systems, and should use Counseling codes in place of E/M codes (99211-15).</p>	CODES TO IDENTIFY AOD DEPENDENCE	NOT INCLUDED REMISSION AND OTHER CODES	F10.10 - 10.29, F11.10 - 11.29, F12.10 - 12.29	F10.21, F10.9, F11.21, F11.9, F12.21, F12.9	F13.10 - 13.29, F14.10 - 14.29, F15.10 - 15.29	F13.21, F13.9, F14.21, F14.9, F15.21, F15.9	F16.10 - 16.29, F18.10 - 18.29, F19.10 - 19.29	F16.21, F16.9, F18.21, F18.9, F19.21, F19.9
CODES TO IDENTIFY AOD DEPENDENCE	NOT INCLUDED REMISSION AND OTHER CODES									
F10.10 - 10.29, F11.10 - 11.29, F12.10 - 12.29	F10.21, F10.9, F11.21, F11.9, F12.21, F12.9									
F13.10 - 13.29, F14.10 - 14.29, F15.10 - 15.29	F13.21, F13.9, F14.21, F14.9, F15.21, F15.9									
F16.10 - 16.29, F18.10 - 18.29, F19.10 - 19.29	F16.21, F16.9, F18.21, F18.9, F19.21, F19.9									

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>LBP – Use of Imaging Studies for Low Back Pain MIPS Measure #312 Administrative measure</p> <p>The percentage of members with a primary diagnosis of low back pain who did NOT have an imaging study (plain X-ray, MRI, CT scan) within 28 days of the diagnosis.</p> <p>The intake period is 1/1 to 12/3 each year.</p>	<p>Members 18 to 50 years will NOT receive imaging studies within 28 days of the initial diagnosis of low back pain.</p> <p>This includes a plain X-ray</p> <p>Consider referral for physical therapy evaluation before X-rays are ordered.</p>	<p>Claims:</p> <ul style="list-style-type: none"> ▪ Submit a claim with a code for low back pain with first symptom of low back pain. ▪ Submit a claim with code for exclusion if appropriate. <i>Per NCQA HEDIS exclusion specifications: "Any member who had a diagnosis for which imaging is clinically appropriate. Any of the following meet criteria:"</i> <ul style="list-style-type: none"> ▪ Cancer or a history of cancer ▪ Neurologic impairment ▪ HIV ▪ Prolonged Use of Corticosteroids ▪ IV drug use ▪ Recent trauma ▪ Major organ transplant ▪ Spinal infection in previous year <p>Medical record documentation not applicable.</p>

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>MPM – Annual Monitoring for Patients on Persistent Medications Administrative measure</p> <p>The percentage of members ≥ 18 years of age who received 180 + days of medication for a select therapeutic agent and at least one monitoring event in the measurement year.</p> <p>The measurement period is 1/1 to 12/31 of each year.</p>	<p>Members ≥ 18 years old who remain on an ACE/ARB, or a diuretic medication for 180 days will have lab tests done for the following:</p> <p>MPM 1 - ACE/ARB - K+, creatinine</p> <p>MPM 3 - diuretics - K+, creatinine</p>	<p>Claims:</p> <ul style="list-style-type: none"> ▪ Receipt of a claim for laboratory testing for required labs during the measurement year. <ul style="list-style-type: none"> > ACE & ARB - at least one serum potassium and creatinine > Diuretics - at least one serum potassium and creatinine <p>Medical record documentation not applicable.</p> <p>Does not apply to Medicare patients.</p>

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>MMA – Medication Management for People With Asthma MIPS Measure #444 Administrative measure</p> <p>The percentage of members 5-64 years of age during the measurement year who were identified as having persistent asthma and were dispensed appropriate medications that they remained on during the treatment period. Two rates are reported:</p> <ul style="list-style-type: none"> ▪ 50% adherence with controller medication ▪ 75% adherence with controller medication <p>The measurement period is 1/1 to 12/31 of each year.</p>	<p>Members with persistent asthma will be dispensed asthma control medications and will be compliant with use of the medication at least 75% of the treatment period.</p> <p>Assess member compliance with use of medication as prescribed.</p> <p>Consider refill x 11 (1 per month) or 90 day supply.</p> <p><i>*Treatment period begins on the 'earliest prescription dispensing date for any asthma controller medication during the measurement year through the last day (12/31) of the measurement year'.</i></p>	<p>Claims:</p> <ul style="list-style-type: none"> ▪ Receipt of claims for asthma controller medication throughout the measurement year that will total 75% compliance. <p>Medical record documentation not applicable.</p> <p>Not applicable to Medicare patients.</p> <p><i>NCQA will post a comprehensive list of medications and NDC codes to www.ncqa.org in November of the measurement year.</i></p>

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL										
<p>NCS – Non-Recommended Cervical Cancer Screen for Adolescent Females Administrative measure MIPS measure #443</p> <p>The percentage of females 16-20 years of age who were screened unnecessarily for cervical cancer.</p> <p>The measurement period is 1/1 to 12/31 of the current year.</p>	<p>Females 16-20 years of age will not be screened for cervical cancer unless there is a clinical reason for the screening.</p> <p>Lower is better.</p>	<p>Claims:</p> <ul style="list-style-type: none"> Appropriate exclusion diagnosis history must be included in the claim for cervical cancer screening in a female age 16-20. <table border="1" data-bbox="682 347 1312 508"> <thead> <tr> <th colspan="2">EXCLUSIONS</th> </tr> </thead> <tbody> <tr> <td>Cervical Cancer History</td> <td>Z85.41, C53.0, D06.0</td> </tr> <tr> <td>HIV disease</td> <td>B20</td> </tr> <tr> <td>Asymptomatic HIV state</td> <td>Z21</td> </tr> <tr> <td>Disorders of the Immune System</td> <td>D80, D81.0, D81.1, D81.2, D81.4, D81.6, D81.7, D81.89, D81.9, D82, D83, D84, D89.3, D89.810-D89.9</td> </tr> </tbody> </table> <p>Medical record documentation not applicable.</p>	EXCLUSIONS		Cervical Cancer History	Z85.41, C53.0, D06.0	HIV disease	B20	Asymptomatic HIV state	Z21	Disorders of the Immune System	D80, D81.0, D81.1, D81.2, D81.4, D81.6, D81.7, D81.89, D81.9, D82, D83, D84, D89.3, D89.810-D89.9
EXCLUSIONS												
Cervical Cancer History	Z85.41, C53.0, D06.0											
HIV disease	B20											
Asymptomatic HIV state	Z21											
Disorders of the Immune System	D80, D81.0, D81.1, D81.2, D81.4, D81.6, D81.7, D81.89, D81.9, D82, D83, D84, D89.3, D89.810-D89.9											

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>OMW – Osteoporosis Management in Women Who Had a Fracture MIPS Measure #418 Administrative measure</p> <p>The percentage of women 67-85* years of age who suffered a fracture and had either a Bone Mineral Density (BMD) test or prescription for a drug to treat osteoporosis in the six months after the fracture.</p> <p>The measurement period is 7/1 of the prior year to 6/30 of the current year.</p>	<p>Members 67-85 years of age, who had a fracture, will have a BMD within 6 months of the date of fracture.</p> <p>Consider BMD every 2 years in this age group.</p> <p>Medicare only.</p>	<p>Claims:</p> <ul style="list-style-type: none"> Receipt of a claim for BMD within 6 months of a fracture. Receipt of claim for medication to treat osteoporosis within 6 months of the fracture. <p>Medical Record documentation not applicable.</p> <p>Exclusions:</p> <ul style="list-style-type: none"> Members who have had a bone density test during the 24 months prior to the fracture. Members who during the 12 months prior to the fracture received a dispensed prescription or had an active prescription to treat osteoporosis. Members who had a claim/encounter for osteoporosis therapy in the 12 months prior to the fracture. *Members 65 years of age and older living in long-term in institutional settings. <p><i>A comprehensive list of medications and NDC codes can be found at www.ncqa.org</i></p>

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL																
<p>PBH – Persistence of Beta Blocker Treatment after a Heart Attack MIPS Measure #442 Administrative measure</p> <p>The percentage of members \geq 18 years of age who were hospitalized and discharged with a diagnosis of AMI and who remained on beta-blocker treatment for six months after discharge.</p> <p>The intake period is 7/1 of the prior year to 6/30 of the current year annually.</p>	<p>Member's \geq 18 years of age with new diagnosis of AMI will remain on beta-blocker treatment for six months after hospital discharge.</p> <p>Consider 90 day supply or refills x 6 if appropriate.</p>	<p>Claims:</p> <ul style="list-style-type: none"> Receipt of pharmacy claims for 180-day supply of a beta blocker medication. Submit a claim if member has one of the following exclusions. <p>Medical record documentation not applicable.</p> <table border="1" data-bbox="686 317 1315 557"> <thead> <tr> <th colspan="2" data-bbox="686 317 1315 342">EXCLUSIONS: ICD-10-CM DIAGNOSIS</th> </tr> </thead> <tbody> <tr> <td data-bbox="686 342 1043 368">Asthma</td> <td data-bbox="1043 342 1315 368">J45.2 – J45.52, J45.901 – J45.998</td> </tr> <tr> <td data-bbox="686 368 1043 394">Hypotension</td> <td data-bbox="1043 368 1315 394">I95.0 – 95.3, I95.81 – I95.89</td> </tr> <tr> <td data-bbox="686 394 1043 446">Heart block >1 degree</td> <td data-bbox="1043 394 1315 446">I44.1 – I44.7 (excluding I44.3), I45.0 – I45.3, I45.6, I49.5, I95.0</td> </tr> <tr> <td data-bbox="686 446 1043 472">Sinus bradycardia</td> <td data-bbox="1043 446 1315 472">R00.1</td> </tr> <tr> <td data-bbox="686 472 1043 498">COPD</td> <td data-bbox="1043 472 1315 498">J44.0 – J44.9</td> </tr> <tr> <td data-bbox="686 498 1043 524">Obstructive Chronic Bronchitis</td> <td data-bbox="1043 498 1315 524">J41.0 – J42</td> </tr> <tr> <td data-bbox="686 524 1043 550">Chronic conditions due to inhaled fumes/vapors</td> <td data-bbox="1043 524 1315 550">J68.4</td> </tr> </tbody> </table>	EXCLUSIONS: ICD-10-CM DIAGNOSIS		Asthma	J45.2 – J45.52, J45.901 – J45.998	Hypotension	I95.0 – 95.3, I95.81 – I95.89	Heart block >1 degree	I44.1 – I44.7 (excluding I44.3), I45.0 – I45.3, I45.6, I49.5, I95.0	Sinus bradycardia	R00.1	COPD	J44.0 – J44.9	Obstructive Chronic Bronchitis	J41.0 – J42	Chronic conditions due to inhaled fumes/vapors	J68.4
EXCLUSIONS: ICD-10-CM DIAGNOSIS																		
Asthma	J45.2 – J45.52, J45.901 – J45.998																	
Hypotension	I95.0 – 95.3, I95.81 – I95.89																	
Heart block >1 degree	I44.1 – I44.7 (excluding I44.3), I45.0 – I45.3, I45.6, I49.5, I95.0																	
Sinus bradycardia	R00.1																	
COPD	J44.0 – J44.9																	
Obstructive Chronic Bronchitis	J41.0 – J42																	
Chronic conditions due to inhaled fumes/vapors	J68.4																	

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>PCE – Pharmacotherapy Management of COPD Exacerbation Administrative measure</p> <p>The percentage of COPD exacerbations for members ≥ 40 years old who had an inpatient or ED visit and were dispensed appropriate medications.</p> <p>Two rates are reported:</p> <ol style="list-style-type: none"> Systemic Corticosteroid dispensed within 14 days of discharge date. Bronchodilator dispensed within 30 days of discharge date. <p>The measurement period is 1/1 to 11/30 of the current year.</p>	<p>Assess if patient was given appropriate medication prescription at the time of discharge.</p> <p>AND</p> <p>has filled the prescription AND is taking medications as prescribed.</p> <p>Prescribe appropriate systemic corticosteroid within 14 days of the discharge date and bronchodilator within 30 days of discharge IF member was not given Rx at the time of discharge.</p>	<p>Claims:</p> <ul style="list-style-type: none"> Receipt of pharmacy claims. <ul style="list-style-type: none"> > For a systemic steroid within 14 days of date of discharge and a bronchodilator within 30 days from inpatient stay or ER visit OR > An adequate supply of either medication for treatment after discharge from ER or Acute Inpatient stay. <p>There are no exclusions to this measure.</p> <p>Medical record documentation not applicable.</p> <p><i>A comprehensive list of medications and NDC codes can be found at www.ncqa.org</i></p>
<p>PPC – Prenatal and Postpartum Care Hybrid measure</p> <p>Timeliness of Prenatal Care The percentage of deliveries that received a prenatal visit in the first trimester.</p> <p>Postpartum Care The percentage of deliveries that had a postpartum visit on or between 21 & 56 days after delivery.</p> <p>The intake period is 11/6 of the prior year to 11/5 of the current year.</p>	<p>Members will receive a prenatal visit in the first trimester of pregnancy (or within 45 days of enrollment in Blue Cross NC).</p> <p>Members will receive a postpartum visit with their provider between day 21 and day 56 postpartum.</p>	<p>Claims:</p> <ul style="list-style-type: none"> All providers must submit a claim for the prenatal visit on the date of service using the following codes: 0500F or 0501F and the appropriate ICD-10 diagnosis. All providers must submit a claim for the post partum visit on the date of service using the following code: 0503F and the ICD 10 diagnosis code for Postpartum Care Z39.2. For Global Billing - You must submit an additional claim with the dates of the prenatal and postpartum visits. Refer to Corporate Reimbursement Policy OR <p>Medical record documentation:</p> <ul style="list-style-type: none"> Date service rendered Service rendered EDC or LMP or Date of delivery

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL						
<p>SPC – Statin Therapy for Patients with Cardiovascular Disease Administrative measure</p> <p>The percentage of males 21 – 75 years of age and females 40 – 75 years of age during the measurement year, who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria:</p> <p>Two rates are reported:</p> <ol style="list-style-type: none"> Received Statin Therapy. Members who were dispensed at least one high-intensity or moderate-intensity statin medication during the measurement year. Statin Adherence 80%. Members who remained on a high-intensity or moderate-intensity statin medication for at least 80% of the treatment period. <p>The measurement period is 1/1 – 12/31 of the current year.</p>	<p>Members identified as having clinical atherosclerotic cardiovascular disease (ASCVD) will be prescribed and then maintain 80% adherence on a Statin Medication.</p>	<p>Claims:</p> <ul style="list-style-type: none"> Receipt of pharmacy claims for a high intensity or moderate intensity statin medication during the measurement year. Receipt of pharmacy claims for a high intensity or moderate intensity statin medication throughout the measurement year that will total 80% compliance. <p>High- and Moderate-Intensity Statin Medications</p> <table border="1" data-bbox="682 363 1310 660"> <thead> <tr> <th data-bbox="682 363 815 391">DESCRIPTION</th> <th data-bbox="815 363 1310 391">PRESCRIPTION</th> </tr> </thead> <tbody> <tr> <td data-bbox="682 391 815 474">High-intensity statin therapy</td> <td data-bbox="815 391 1310 474"> <ul style="list-style-type: none"> Atorvastatin 40-80 mg Amlodipine-atorvastatin 40-80 mg Ezetimibe-atorvastatin 40-80-mg Rosuvastatin 20-40 mg Simvastatin 80 mg Ezetimibe-simvastatin 80 mg </td> </tr> <tr> <td data-bbox="682 474 815 660">Moderate-intensity statin therapy</td> <td data-bbox="815 474 1310 660"> <ul style="list-style-type: none"> Atorvastatin 10-20 mg Amlodipine-atorvastatin 10-20 mg Ezetimibe-atorvastatin 10-20 mg Rosuvastatin 5-10 mg Simvastatin 20-40 mg Ezetimibe-simvastatin 30-40 mg Niacin-simvastatin 20-40 mg Sitagliptin-simvastatin 20-40 mg Pravastatin 40-80 mg Lovastatin 40 mg Niacin-lovastatin 40 mg Fluvastatin XL 80 mg Fluvastatin 40 mg bid Pitavastatin 204 mg </td> </tr> </tbody> </table> <p>There are no exclusions to this measure.</p> <p>Medical record documentation not applicable.</p> <p><i>A comprehensive list of medications and NDC codes can be found at www.ncqa.org</i></p>	DESCRIPTION	PRESCRIPTION	High-intensity statin therapy	<ul style="list-style-type: none"> Atorvastatin 40-80 mg Amlodipine-atorvastatin 40-80 mg Ezetimibe-atorvastatin 40-80-mg Rosuvastatin 20-40 mg Simvastatin 80 mg Ezetimibe-simvastatin 80 mg 	Moderate-intensity statin therapy	<ul style="list-style-type: none"> Atorvastatin 10-20 mg Amlodipine-atorvastatin 10-20 mg Ezetimibe-atorvastatin 10-20 mg Rosuvastatin 5-10 mg Simvastatin 20-40 mg Ezetimibe-simvastatin 30-40 mg Niacin-simvastatin 20-40 mg Sitagliptin-simvastatin 20-40 mg Pravastatin 40-80 mg Lovastatin 40 mg Niacin-lovastatin 40 mg Fluvastatin XL 80 mg Fluvastatin 40 mg bid Pitavastatin 204 mg
DESCRIPTION	PRESCRIPTION							
High-intensity statin therapy	<ul style="list-style-type: none"> Atorvastatin 40-80 mg Amlodipine-atorvastatin 40-80 mg Ezetimibe-atorvastatin 40-80-mg Rosuvastatin 20-40 mg Simvastatin 80 mg Ezetimibe-simvastatin 80 mg 							
Moderate-intensity statin therapy	<ul style="list-style-type: none"> Atorvastatin 10-20 mg Amlodipine-atorvastatin 10-20 mg Ezetimibe-atorvastatin 10-20 mg Rosuvastatin 5-10 mg Simvastatin 20-40 mg Ezetimibe-simvastatin 30-40 mg Niacin-simvastatin 20-40 mg Sitagliptin-simvastatin 20-40 mg Pravastatin 40-80 mg Lovastatin 40 mg Niacin-lovastatin 40 mg Fluvastatin XL 80 mg Fluvastatin 40 mg bid Pitavastatin 204 mg 							

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>SPD – Statin Therapy for Patients with Diabetes Administrative measure</p> <p>The percentage of members 40-75 years of age during the measurement year with diabetes who do not have clinical atherosclerotic disease (ASCVD) who met the following criteria:</p> <p>Two rates are reported:</p> <ol style="list-style-type: none"> <i>Received Statin Therapy.</i> Members who were dispensed at least one statin medication of any intensity during the measurement year. <i>Statin Adherence 80%.</i> Members who remained on a statin medication of any intensity for at least 80% of the treatment period. <p>The measurement period is 1/1 to 12/31 of the current year.</p>	<p>Members identified as having Diabetes who do not have atherosclerotic cardiovascular disease (ASCVD) will be prescribed and then maintain 80% adherence on a statin medication.</p>	<p>Claims:</p> <ul style="list-style-type: none"> Receipt of pharmacy claims for a statin medication during the measurement year. Receipt of pharmacy claims for a statin medication throughout the measurement year that will total 80% compliance. <p>There are no exclusions to this measure.</p> <p>Medical record documentation not applicable.</p> <p><i>A comprehensive list of medications and NDC codes can be found at www.ncqa.org</i></p>

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>SPR – Use of Spirometry Testing in the Assessment and Diagnosis of COPD MIPS Measure #51 Administrative measure</p> <p>The percentage of members ≥ 40 years of age with a new diagnosis of COPD who received spirometry testing to confirm the diagnosis.</p> <p>The intake period is 7/1 of the prior year to 6/30 of the current year.</p>	<p>Members ≥ 40 years old with a new or newly active diagnosis of COPD will have spirometry testing completed to confirm the diagnosis.</p>	<p>Claims:</p> <ul style="list-style-type: none"> Submit a claim for spirometry testing on the date of service using appropriate CPT code. <p>Medical record documentation not applicable.</p>

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>URI – Appropriate Treatment for Children With Upper Respiratory Infection MIPS Measure #65 Administrative measure</p> <p>The % of children 3 months-18 years of age who were diagnosed with upper respiratory infection (URI) and were NOT dispensed an antibiotic prescription.</p> <p>The Intake period is 7/1 of the prior year to 6/30 of the current year.</p>	<p>Antibiotics will NOT be prescribed to children who are diagnosed with URI only.</p> <p>If there is another diagnosis that requires antibiotic treatment you need to add that coding information to your claim.</p>	<p>Claims:</p> <ul style="list-style-type: none"> Submit a claim for all additional <u>competing diagnoses requiring antibiotic therapy</u> on or within 3 days after the date of claim for URI. <p>Medical record documentation not applicable.</p>

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>W15 – Well-Child Visits in the First 15 Months of Life Administrative measure</p> <p>The percentage of members who turned 15 months old during the measurement year and who had: none, one, 1, 2, 3, 4, 5, 6, or more well-child visits. (7 rates are calculated)</p> <p>The measurement period is 1/1 to 12/31 of the current year.</p>	<p>Children should have 6 or more well-child visits by the time the child is 15 months old.</p>	<p>Claims:</p> <ul style="list-style-type: none"> Submit a claim for all member visits with proper coding for the visit service. <p>Medical record documentation not applicable.</p>

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>W34 – Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life Administrative measure The percentage of members 3-6 years of age who had one or more well-child visits with a PCP during the measurement year. The measurement period is 1/1 to 12/31 of the current year.</p>	<p>Every child between 3 and 6 years of age will have a well-child visit at least annually.</p>	<p>Claims:</p> <ul style="list-style-type: none"> Submit a claim for all member visits with proper coding for the visit service. <p>Medical record documentation not applicable.</p>

WCC – Weight Assessment & Counseling for Nutrition & Physical Activity for Children & Adolescents
<p>MIPS Measure #239 – Hybrid measure The percentage of members 3-17 years of age who had an outpatient visit with a PCP or OB/GYN & had the following during the measurement year (1/1 - 12/31):</p>

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL										
<p>WCC – BMI Percentile</p>	<p>Members will be assessed for height, weight, and BMI percentile during the measurement year.</p>	<p>Claims:</p> <ul style="list-style-type: none"> Submit a claim including the appropriate code below. <table border="1" data-bbox="682 699 1310 837"> <thead> <tr> <th data-bbox="682 699 949 725">ICD 10 CODES</th> <th data-bbox="949 699 1310 725">PERCENTILE</th> </tr> </thead> <tbody> <tr> <td data-bbox="682 725 949 751">Z68.51</td> <td data-bbox="949 725 1310 751">Pediatric < 5th</td> </tr> <tr> <td data-bbox="682 751 949 777">Z68.52</td> <td data-bbox="949 751 1310 777">Pediatric ≥ 5th - <85th</td> </tr> <tr> <td data-bbox="682 777 949 802">Z68.53</td> <td data-bbox="949 777 1310 802">Pediatric ≥ 85th ≤ 95th</td> </tr> <tr> <td data-bbox="682 802 949 837">Z68.54</td> <td data-bbox="949 802 1310 837">Pediatric ≥ 95th</td> </tr> </tbody> </table> <p>Medical record documentation of:</p> <ul style="list-style-type: none"> Height, Weight & BMI percentile or BMI percentile plotted on age-growth chart during the measurement year. The height, weight & BMI must be from the same data source. 	ICD 10 CODES	PERCENTILE	Z68.51	Pediatric < 5th	Z68.52	Pediatric ≥ 5th - <85th	Z68.53	Pediatric ≥ 85th ≤ 95th	Z68.54	Pediatric ≥ 95th
ICD 10 CODES	PERCENTILE											
Z68.51	Pediatric < 5th											
Z68.52	Pediatric ≥ 5th - <85th											
Z68.53	Pediatric ≥ 85th ≤ 95th											
Z68.54	Pediatric ≥ 95th											

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>WCC – Counseling for Nutrition</p> <p>Documentation of counseling for nutrition or referral for nutrition education during the measurement (current) year as identified by administrative data or medical record review.</p>	<p>Members will be counseled on nutrition during the measurement year.</p>	<p>Claims:</p> <ul style="list-style-type: none"> ▪ Submit a claim with the appropriate code: <ul style="list-style-type: none"> Z71.3 Dietary Counseling and surveillance. G0447 Face to Face behavioral counseling for obesity - 15 minutes. <p>Medical record documentation of:</p> <ul style="list-style-type: none"> ▪ A note indicating the date of service and at least one of the following: <ul style="list-style-type: none"> > Anticipatory guidance for physical activity. Discussion of nutrition behavior (i.e. eating or diet behaviors). > Checklist indicating nutrition was addressed. > Educational materials on nutrition given to the member during face to face visits. > Anticipatory guidance for nutrition. > Counseling or referral for nutrition education. > Weight or obesity counseling.

HEDIS QUALITY MEASURE	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>WCC – Counseling for Physical Activity</p> <p>Documentation of counseling for physical activity or referral for physical activity during the measurement year as identified by administrative data or medical record review.</p>	<p>Members will be counseled on physical activity in the measurement year.</p>	<p>Claims:</p> <ul style="list-style-type: none"> ▪ Submit a claim with the appropriate code if applicable. G0447 Face to face behavioral counseling for obesity - 15 min. <p>Medical record documentation:</p> <ul style="list-style-type: none"> ▪ A note indicating the date of service and at least one of the following: <ul style="list-style-type: none"> > Discussion of current physical activity behaviors (i.e. exercise routine, sports activities, exam for sports participation). > Checklist indicating physical activity was addressed. > Counseling or referral for physical activity. > Member received educational materials on physical activity during a face-to-face visit. > Anticipatory guidance for physical activity.

MEDICARE PART D PHARMACY MEASURES

MEDICARE PART D PHARMACY MEASURES	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>HRM – High Risk Medications Administrative measure</p> <p>The Percentage of Medicare Part D beneficiaries 65 years and older who receive 2 or more prescriptions for the same HRM drug with high risk of side effects in the elderly.</p> <p>The measurement period is 1/1 – 12/31 of the current year.</p>	<p>Patients 65 and older will NOT receive 2 or more prescriptions for HRM.</p> <p>If an HRM is indicated, limit use to the shortest time and lowest dose possible without refills</p>	<p>Claims:</p> <ul style="list-style-type: none"> Information for this measure is based on claims data for prescription drugs filled by the members through December 31 of the measurement year. <p>There is no reporting required from the provider.</p> <p>Medical Record documentation not applicable.</p>

MEDICARE PART D PHARMACY MEASURES

MEDICARE PART D PHARMACY MEASURES	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>Rx - Cholesterol Adherence Medication Adherence for Cholesterol (Statins)</p> <p>The Percentage of Medicare Part D beneficiaries 18 years or older who adhere to their prescribed drug therapy for statin cholesterol medications during the measurement period.</p> <p>The measurement period is 1/1 – 12/31 of the current year.</p>	<p>Consider 90 day supply of medication.</p> <p>Educate your patient re: medication compliance & risk factors.</p> <p>Assess compliance and remove barriers to compliance.</p>	<p>Claims:</p> <ul style="list-style-type: none"> Information for this measure is based on claims data for prescription drugs filled by the members through December 31 of the measurement year. <p>There is no reporting required from the provider.</p> <p>Medical Record documentation not applicable.</p> <p>Adherence defined as: <i>A proportion of days covered (PDC) at 80% or over for statin cholesterol medication(s) during the measurement period.</i></p>

MEDICARE PART D PHARMACY MEASURES

MEDICARE PART D PHARMACY MEASURES	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>Rx - Hypertension Adherence</p> <p>Medication Adherence for Hypertension (RAS antagonists) Administrative measure</p> <p>The Percentage of Medicare Part D beneficiaries 18 years or older who adhere to their prescribed drug therapy for renin angiotensin system (RAS) antagonists [angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), or direct renin inhibitor medications].</p> <p>The measurement period is 1/1 – 12/31 of the current year.</p>	<p>Consider 90 day supply of medication.</p> <p>Educate your patient re: medication compliance and risk factors.</p> <p>Assess compliance and remove barriers to compliance.</p>	<p>Claims:</p> <ul style="list-style-type: none"> Information for this measure is based on claims data for prescription drugs filled by the members through December 31 of the measurement year. <p>There is no reporting required from the provider.</p> <p>Medical Record documentation not applicable.</p> <p>Adherence defined as: <i>A proportion of days covered (PDC) at 80% or over for appropriate medication(s) during the measurement period.</i></p>

MEDICARE PART D PHARMACY MEASURES

MEDICARE PART D PHARMACY MEASURES	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>Rx - Diabetes Medication Adherence</p> <p>Medication Adherence for Diabetes Medications</p> <p>The percentage of Medicare Part D beneficiaries 18 years or older who adhere to their prescribed drug therapy across classes of diabetes medications: biguanides, sulfonylureas, thiazolidinediones, and DiPeptidyl Peptidase (DPP)-IV Inhibitors, incretin mimetics, and meglitinides.</p> <p>The measurement period is 1/1 – 12/31 of the current year.</p>	<p>Consider 90 day supply of medication.</p> <p>Educate your patient re: medication compliance and risk factors.</p> <p>Assess compliance and remove barriers to compliance.</p>	<p>Claims:</p> <ul style="list-style-type: none"> Information for this measure is based on claims data for prescription drugs filled by the members through December 31 of the measurement year. <p>There is no reporting required from the provider.</p> <p>Medical Record documentation not applicable.</p> <p>Adherence defined as: <i>A proportion of days covered (PDC) at 80% or over for appropriate medication(s) during the measurement period.</i></p> <p>Exclusion: Members who take insulin are not included in this measure.</p>

MEDICARE PART D PHARMACY MEASURES

MEDICARE PART D PHARMACY MEASURES	CLINICAL GOAL	CRITERIA TO MEET THE GOAL
<p>Rx - Statin Use in Persons with Diabetes (SUPD)</p> <p>The percentage of Medicare Part D beneficiaries between 40 and 75 years old who received at least two diabetes medication fills and also received a statin medication during the measurement period.</p> <p>The measurement period is 1/1 to 12/31 of the current year.</p>	<p>Educate your patient re: medication compliance and risk factors.</p> <p>Assess compliance and remove barriers to compliance.</p>	<p>Claims:</p> <ul style="list-style-type: none"> ▪ Information for this measure is based on claims data for prescription drugs filled by the members through December 31 of the measurement year. <p>There is no reporting required from the provider.</p> <p>Medical Record documentation not applicable.</p> <p>Exclusion: Members who are in Hospice are not included in this measure.</p>

APPENDIX 1.

ICD-10-CM BMI CODES

Z68.1	Body mass index (BMI) 19 or less	adult
Z68.20	Body mass index (BMI) 20.0-20.9	adult
Z68.21	Body mass index (BMI) 21.0-21.9	adult
Z68.22	Body mass index (BMI) 22.0-22.9	adult
Z68.23	Body mass index (BMI) 23.0-23.9	adult
Z68.24	Body mass index (BMI) 24.0-24.9	adult
Z68.25	Body mass index (BMI) 25.0-25.9	adult
Z68.26	Body mass index (BMI) 26.0-26.9	adult
Z68.27	Body mass index (BMI) 27.0-27.9	adult
Z68.28	Body mass index (BMI) 28.0-28.9	adult
Z68.29	Body mass index (BMI) 29.0-29.9	adult
Z68.30	Body mass index (BMI) 30.0-30.9	adult
Z68.31	Body mass index (BMI) 31.0-31.9	adult

Z68.32	Body mass index (BMI) 32.0-32.9	adult
Z68.33	Body mass index (BMI) 33.0-33.9	adult
Z68.34	Body mass index (BMI) 34.0-34.9	adult
Z68.35	Body mass index (BMI) 35.0-35.9	adult
Z68.36	Body mass index (BMI) 36.0-36.9	adult
Z68.37	Body mass index (BMI) 37.0-37.9	adult
Z68.38	Body mass index (BMI) 38.0-38.9	adult
Z68.39	Body mass index (BMI) 39.0-39.9	adult
Z68.41	Body mass index (BMI) 40.0-44.9	adult
Z68.42	Body mass index (BMI) 45.0-49.9	adult
Z68.43	Body mass index (BMI) 50.0-59.9	adult
Z68.44	Body mass index (BMI) 60.0-69.9	adult
Z68.45	Body mass index (BMI) 70 or >	adult

APPENDIX 2. BMI CHART

WEIGHT (POUNDS)	HEIGHT (FEET, INCHES)					
	5'0"	5'3"	5'6"	5'9"	6'0"	6'3"
140	27	25	23	21	19	18
150	29	27	24	22	20	19
160	31	28	26	24	22	20
170	33	30	28	25	23	21
180	35	32	29	27	25	23
190	37	34	31	28	26	24
200	39	36	32	30	27	25
210	41	37	34	31	29	26
220	43	39	36	33	30	28
230	45	41	37	34	31	29
240	47	43	39	36	33	30
250	49	44	40	37	34	31

APPENDIX 3.

MEASURES USED IN OVERALL MEDICARE STAR RATINGS

The Centers for Medicare & Medicaid Services (CMS) uses a five-star quality rating system to promote improvement in quality. The following weighted Measures are utilized when calculating an overall Medicare Star Rating:

	MEASUREMENT	WEIGHT
Rx	Cholesterol Adherence (Statins)	3
Rx	Hypertension Adherence	3
Rx	Diabetes Medication Adherence	3
CDC	HbA1c Poor Control >9%	3
OMW	Osteoporosis Management	1
COL	Colorectal Cancer Screening	1
CDC	Medical Attention for Nephropathy	1
ABA	Adult BMI Assessment	1
ART	Drug Therapy for Rheumatoid Arthritis	1
BCS	Breast Cancer Screening	1
CDC	Eye Exam	1

APPENDIX 4.

MIPS-HEDIS MEASURE CROSSWALK

HEDIS MEASURE		MIPS MEASURE NUMBER	MIPS MEASURE TYPE	MEASURE COMPARISON INFO
AAB	Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis	#116	Process	Exact match
ABA	Adult BMI Assessment	#128	Process	MIPS: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan – Percentage of patients aged 18 years and older with a BMI documented during the current encounter or during the previous six months AND with a BMI outside of normal parameters, a follow up plan is documented during the encounter or during the previous six months of the current encounter. Normal Parameters: Age 18 years and older BMI ≥ 18.5 and < 25 kg/m ² .
ADD	Follow-up Care for Children Prescribed ADHD Medication	#366	Process	Exact match
AMM	Antidepressant Medication Management	#9	Process	Exact match
ART	Disease-Modifying Anti-Rheumatic Drug Therapy Rheumatoid Arthritis	#180	Process	MIPS: Rheumatoid Arthritis (RA): Glucocorticoid management Percentage of patients aged 18 years and older with a diagnosis of rheumatoid arthritis (RA) who have been assessed for glucocorticoid use and, for those on prolonged doses of prednisone ≥ 10 mg daily (or equivalent) with improvement or no change in disease activity, documentation of glucocorticoid management plan within 12 months.
BCS	Breast Cancer Screening	#112	Process	Exact match
CBP	Controlling High Blood Pressure	#236	Outcome	HEDIS allows $<150/90$ for ages 60-85 without diabetes, MIPS is $<140/90$

HEDIS MEASURE		MIPS MEASURE NUMBER	MIPS MEASURE TYPE	MEASURE COMPARISON INFO
CCS	Cervical Cancer Screening	#309	Process	Exact match
CDC	Comprehensive Diabetes Care			Exact match
	• Eye Exam Performed	#117	Process	
	• HbA1c Poor Control >9%	#1	Outcome	
	• Medical Attention for Nephropathy	#119	Process	
CHL	Chlamydia Screening for Women	#310	Process	Exact match
CIS	Childhood Immunization Status Combo 10	#240	Process	Exact match
COL	Colorectal Cancer Screening	#113	Process	Exact match
CWP	Appropriate Testing for Children with Pharyngitis	#66	Process	Exact match
FUH	Follow-up after Hospitalization for Mental Illness – 7-day and 30-day rates	#391	Process	Exact match
IET	Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment	#394	Process	Exact match
LBP	Use of Imaging Studies for Low Back Pain	#312	Process	Exact match
MMA	Medication Management for People with Asthma – 75% rate	#444	Process	Exact match
NCS	Non-Recommended Cervical Cancer Screening for Adolescent Females	#443	Process	Exact match
OMW	Osteoporosis Management in Women Who Had a Fracture	#418	Process	MIPS age Criteria 50-85; HEDIS age criteria 67-85, Medicare only.

HEDIS MEASURE		MIPS MEASURE NUMBER	MIPS MEASURE TYPE	MEASURE COMPARISON INFO
PBH	Persistence of a Beta Blocker after Heart Attack	#442	Process	Exact match
SPR	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	#51	Process	MIPS age criteria ≥ 18 ; HEDIS age criteria ≥ 40
URI	Appropriate Treatment of Children with Upper Respiratory Infection	#65	Process	Exact match
WCC	Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents – all 3 rates	#239	Process	Exact match

Last Updated 11/1/2017.

Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.